PRX 00023

To address the development of early anxiety disorders across the lifespan, the High USV line of rats was bred based on rates of… Expand

PRX-00023, a serotonin 1A receptor agonist, was designed to provide high potency and selectivity for its target. To assess the… Expand

BACKGROUND The serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor likely plays a critical role in anxiety pathophysiology… Expand

PRX-00023 is a novel, nonazapirone 5-HT1A agonist in clinical development for treatment of affective disorders. The objectives of… Expand

EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist… Expand

 

We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of… Expand

 

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand